<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04200235</url>
  </required_header>
  <id_info>
    <org_study_id>HR0171401-102</org_study_id>
    <nct_id>NCT04200235</nct_id>
  </id_info>
  <brief_title>A Trial of Dexmedetomidine Hydrochloride Nasal Spray in Preoperative Sedation of Children</brief_title>
  <official_title>Study on Pharmacokinetics and Clinical Efficacy of Dexmedetomidine Hydrochloride Nasal Spray for Preoperative Sedation in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to evaluate the efficacy, safety and the population
      pharmacokinetic characteristics of dexmedetomidine hydrochloride nasal spray for preoperative
      sedation in children
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 6, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Dexmedetomidine hydrochloride nasal spray compared with placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK Cmax</measure>
    <time_frame>0 to 1 hour after administration</time_frame>
    <description>Maximum blood concentration (Cmax)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who parent-child separation successful</measure>
    <time_frame>0 minute to 45 minutes after administration: every 15 minutes after administration</time_frame>
    <description>The FUNK scale is a scale of 1 to 4 for sedation, anxiety, and separation from parents. Separation success defined as a scale of 3 or 4 per item.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who the Ramsay score is satisfactory at least once</measure>
    <time_frame>0 minute to 45 minutes after administration: every 5 minutes after administration</time_frame>
    <description>Sedation level using the Ramsay scale. Ramsay Satisfaction defined as a scale of 2, 3, or 4;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who the UMSS Scale is satisfactory at least once</measure>
    <time_frame>0 minute to 45 minutes after administration: every 5 minutes after administration</time_frame>
    <description>Sedation level using the University of Michigan Sedation Scale. UMSS satisfaction defined as a scale of 3, 4, 5, or 6;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total consumption of propofol(mg) during general anesthesia</measure>
    <time_frame>From the beginning of anesthesia to the end of surgical operation up to 4 hours</time_frame>
    <description>Total consumption of propofol(mg) during general anesthesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total consumption of opioid analgesic(μg) during general anesthesia</measure>
    <time_frame>From the beginning of anesthesia to the end of surgical operation up to 4 hours</time_frame>
    <description>Total consumption of opioid analgesic(μg) during general anesthesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of anesthesia awakening</measure>
    <time_frame>Up to 4 hours after the end of surgical operation</time_frame>
    <description>Time of anesthesia awakening</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with postoperative agitation</measure>
    <time_frame>Up to 4 hours after the end of surgical operation</time_frame>
    <description>Proportion of subjects with postoperative agitation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Preoperative Sedation</condition>
  <arm_group>
    <arm_group_label>High weight group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High weight group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low weight group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low weight group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine hydrochloride nasal spray</intervention_name>
    <description>In the low weight group, 18 subjects will receive a low dose of dexmedetomidine nasal spray.
In the high weight group, 18 subjects will receive a high dose of dexmedetomidine nasal spray.</description>
    <arm_group_label>High weight group</arm_group_label>
    <arm_group_label>Low weight group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine hydrochloride nasal spray blank preparation.</intervention_name>
    <description>In the low weight group, 6 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.
In the high weight group, 6 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.</description>
    <arm_group_label>High weight group</arm_group_label>
    <arm_group_label>Low weight group</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Able and willing to provide a written informed consent

          2. Male or female

          3. Subjects requiring elective general anesthesia surgery

          4. Conform to the ASA Physical Status Classification

          5. Meet the weight standard

        Exclusion Criteria:

          1. Not suitable for nasal spray

          2. Pediatric populations requiring special care or court/social welfare supervision

          3. Subjects who had been under general anesthesia were randomized

          4. Subjects with mental disorders and cognitive impairment；Subject with a history of
             epilepsy

          5. Subjects with previous abnormal behavior after medication

          6. Subjects with cardiovascular disease

          7. Clinically significant abnormal clinical laboratory test value

          8. Subjects whose hemoglobin is below the lower limit of normal

          9. Subjects who have either an adrenergic receptor agonist or an antagonist were
             randomized

         10. Participated in clinical trials of other drugs before screening (accepted experimental
             drugs)

         11. A history or possibility of difficult airway

         12. History of hypersensitivity to drug ingredients or components

         13. Other circumstances that the investigator judged inappropriate for participation in
             this clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing children's hospital, capital medical university</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100045</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunyan Guo</last_name>
      <phone>010-59616083</phone>
      <email>bch_ec@163.com</email>
    </contact>
    <investigator>
      <last_name>Jianmin Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fang Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 25, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2019</study_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

